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Abstract 
Short QT Syndrome (SQTS) is an identified genetic 
arrhythmogenic disease associated with abnormally 
abbreviated QT intervals and an increased susceptibility 
to malignant arrhythmia and sudden cardiac death (SCD). 
SQT2 variant (linked to slow delayed rectifier, IKs) of 
SQTS, results from a gain-of-function (V307L) in the 
KCNQ1 subunit of the IKs channel. Pro-arrhythmogenic 
effects of SQT2 have been well characterized, but less is 
known about the pharmacological treatment of SQT2. We 
find that taurine-magnesium coordination compound 
(TMCC) exerted anti-arrhythmic effects with low toxicity. 
Therefore, this study aimed to assess the potential effects 
of TMCC on SQT2. The channel-blocking effect of TMCC 
on IKs in healthy and SQT2 cells were incorporated into 
computer models of human ventricular action potential 
(AP) and into one dimensional transmural tissue 
simulations. In the single-cell model, TMCC prolonged 
cell AP duration at 90% repolarization (APD90). In the 
one dimensional intact model, TMCC prolonged the QT 
interval on the pseudo-ECGs. Thus, the present study 
provides evidence that TMCC can extend the 
repolarization period and APD90 and QT interval, thereby 





SQTS was first discovered by Gussak et al in 2000 as a 
new clinical syndrome related to sudden cardiac death 
(SCD) [1]. SQTS is characterized by an abnormally short 
QT interval, paroxysmal atrial fibrillation (AF), and life-
threatening ventricular fibrillation (VF) due to accelerated 
cellular repolarization. Researchers have focused on the 
pathogenesis and therapy of SQTS. 
To date, mutations in seven genes (KCNH2, KCNQ1, 
KCNJ2, CACN1Ac, CACNB2b, CACNA2D1, and SCN5A) 
have been identified as responsible for types 1 to 7 of 
SQTS (SQT1-SQT7) [2-4]. Therapies for SQTS include 
implantation of an implantable cardioverter defibrillator 
(ICD) and anti-arrhythmic drugs (quinidine, carvedilol, 
and disopyramide) [5-10]. However, ICD is not suitable 
for children. Furthermore, few reports have been 
published on effective pharmacological treatments for 
SQT2 and its mechanism. 
Current research on SQTS is focused on the discovery 
of new therapeutic factors (new mutations, susceptibility 
to disease and drugs, etc) and effective therapeutic drugs. 
SQTS models are often used in the development of new 
drugs. Current models include gene-mutant experimental 
and computer models of SQTS. The gene-mutant model 
is more widely used in experimental studies.  However, 
gene mutations in experiments can only be studied at the 
cellular level. Therefore, in this study, we chose 
mathematical technique to establish computer models of 
SQT2 to study the potential pharmacological effects at 
both cellular and tissue levels. 
Previous studies have demonstrated that taurine 
magnesium coordination compound (TMCC) had 
protective effects against arrhythmias, and had very low 
toxicity [11]. However, little is known about the 
mechanisms of actions of TMCC on SQT2. Furthermore, 
several recent studies have highlighted the power of 
computer models to investigate mechanisms of 
arrhythmias and predict pharmacological effects of drugs. 
Therefore, this study was undertaken to assess the effects 
of TMCC on SQT2 by using computational human 
ventricular cell and tissue models, and pharmacological 
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effects on action potential (AP) duration at 90% 
repolarization (APD90) and QT interval in this variant of 
SQTS. 
 
2. Materials and methods 
The ten Tusscher et al biophysically detailed computer 
model for human endocardial (ENDO), mid-myocardial 
(MIDDLE) and epicardial (EPI) ventricular AP was used 
in this study [12].  
Parameters in the equations for IKs in the model were 
modified to incorporate experimental data of Bellocq et al 
on KCNQ1 V307L mutation-induced changes in IKs 
channel kinetics that include half-activation voltage V0.5, 
slope factor s and activation rate [13]. Following ten 
Tusscher et al, IKs was described as  
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where gKs is the channel maximal conductance, xs is the 
activation variable, Vm is the cell membrane, EKs is the 
channel equilibrium potential. For details of other 
equations please see ten Tusscher et al. 
KCNQ1 V307L mutation-induced changes in IKs 
channel kinetics were described as 
a: Control/wild-type (WT): 
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b: Heterozygous (Het): 
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c: Homozygous (Hom): 
m








                           (8) 
=0.52 ( )
s sx x
original                           (9) 
d: Homozygous with reduced KCNE1 (HomKCNE1red): 
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A model of transmural ventricular tissue was 
constructed using the equation 
m
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where D is the diffusion parameter modelling the 
intercellular electrical coupling via gap junctions. Itot is 
the total ionic current flowing across the cell membrane 
and is modelled by ten Tusscher et al. In simulations, D 
was set to a constant value of 0.4. In the model, D was set 
to be homogeneous throughout the one dimensional 
strand, except for a 5-fold decrease at the EPI-MIDDLE 
border, as previously suggested by Gima and Rudy [14].  
A one-dimensional transmural strand was simulated to 
have a total length of 15.0 mm, of which 3.75 mm was 
ENDO, 5.25 mm was MIDDLE and 6mm was EPI. The 
simulated strand employed a spatial resolution of 0.15 
mm, which generated 25 nodes for ENDO, 35 nodes for 
MIDDLE and 40 nodes for EPI. Differential equation was 
numerically solved by the Euler method with a time step 
of 0.02 ms. 
A computed pseudo-ECG was calculated as an integral 
of the transmural gradient of the cell AP at all positions 
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where a is the radius of the strand, dx is the spatial 
resolution, r is the Euclidean distance. In this study, the 
virtual electrode was placed at a position 2.0 cm away 
from the EPI end of the strand. 
A simple pore block theory was used to model drug-
ion channel binding interactions. The maximum 
conductance of cardiac ion channels was reduced 
according to the Hill equation. The reduction of ion 
currents in the presence of TMCC was determined by 
using half maximal inhibitory concentration (IC50) and 
Hill coefficient (nH) values taken from literatures. The 
blocking potency of the compound on ionic currents is 
shown in Table 1. 
 
Table 1. Cardiac ion currents and conductivities (% of 
original value) in the presence of TMCC [11]. 
 
Current TMCC Dose Conductivities 
IKs 0.01 mm 16.95% 
IKs 0.1 mm 28.33% 
IKs 1 mm 36.94% 
 
3. Results 
Figure 1, Figure 2 and Figure 3 exhibit the time course 
of action potential (AP) with the action-in-action of 
different doses of TMCC under SQT2 Het, Hom and 
HomKCNE1red conditions. These results indicate: (i) the 
KCNQ1 V307L mutation IKs increased more rapidly 
following the AP upstroke, and led to the APD 
abbreviation; (ii) different doses of TMCC prolonged the 
APD, and did not affect the resting potential (RP). 
Figure 4, Figure 5 and Figure 6 show the effects of 
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TMCC on the pseudo-ECG under SQT2 Het, Hom and 
HomKCNE1red conditions. These results indicate: (i) the 
KCNQ1 V307L mutation IKs caused abnormally 
abbreviated QT intervals on the ECG, and decreased the 
height of the T waves; (ii) different doses of TMCC 
prolonged the QT intervals, and increased the height of 
the T waves. 
 
 
Figure 1. Effects of different doses of TMCC on human 
ventricular ENDO cells under the SQT2 Het condition. 
 
 
Figure 2. Effects of different doses of TMCC on human 
ventricular ENDO cells under the SQT2 Hom condition. 
 
 
Figure 3. Effects of different doses of TMCC on human 




Figure 4. Effects of different doses of TMCC on 
computed pseudo-ECGs under the SQT2 Het condition. 
 
 
Figure 4. Effects of different doses of TMCC on 
computed pseudo-ECGs under the SQT2 Hom condition. 
 
 
Figure 4. Effects of different doses of TMCC on 
computed pseudo-ECGs under the SQT2 HomKCNE1red 
condition. 
 
4. Discussion and Conclusion 
In this study, the simulation data indicate that TMCC (i) 
caused the prolongation of APD; (ii) prolonged the QT 
interval on the ECG. These findings represent a 
therapeutic candidate for arrhythmia in SQT2. In future, 
we will consider the factors of inhibiting delayed L-type 
calcium currents and sodium currents, in order to produce 
more accurate data. 
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